The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form ...

VIENNA, Austria — Currently available safety and efficacy data do not provide sufficient evidence to justify the off-label use of bevacizumab in the treatment of age-related macular degeneration, ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s Oncologic Drugs Advisory Committee has voted 12-1 to remove bevacizumab’s indication as a first-line ...

April 27, 2012 — Ophthalmologists often use bevacizumab (Avastin, Genentech) off-label to treat wet age-related macular degeneration (AMD) in part because of lower cost compared with on-label use of ...

Genentech and partner Roche are to add information about a rare brain condition called reversible posterior leukoencephalopathy to the label of their blockbuster cancer drug Avastin (bevacizumab), ...

Roche RHHBY announced that the FDA has approved the label expansion for its oncology drug Avastin (bevacizumab). The FDA approved Avastin in combination with chemotherapy (carboplatin and paclitaxel), ...

Many more patients can now benefit from Avastin’s proven survival benefits Roche announced today that the European Commission (EC) has given its approval for the significantly wider use of its ...

Roche ($RHHBY), maker of pricey wet age-related macular degeneration (AMD) drug Lucentis, has long railed against countries' moves to use its cancer drug Avastin off ...

Cyberknife radiosurgery for liver metastases and primary liver tumors. Background: Bevacizumab was approved by the FDA for use in the first-line treatment of metastatic colon cancer in February, 2004.

MONMOUTH JUNCTION, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ...

While Avastin awaits an FDA decision on its use in breast cancer, it's getting new cautionary language added to its label. Among them: A warning that the Roche drug might interfere with women's ...